腺病毒介导的人GM—CSF基因转染瘤苗体内致瘤性降低的实验研究  

Decreased tumorigenicity of tumor vaccine transefcted with human GM-CSF gene via recombinant adkenoviral vectors

作　　者：刘庆宏[1] 钱海鑫[2] 杨吉成[2] 甘建和[2] 孙倍成[2] 

机构地区：[1]扬州大学医学院附属苏北医院肿瘤外科,扬州225001 [2]苏州医学院附属一院普外科,扬州225006

出　　处：《临床肿瘤学杂志》1997年第4期21-23,共3页Chinese Clinical Oncology

摘　　要：目的:建立以腺病毒为载体的GM—CSF基因转染瘤苗,并对其体内抗肿瘤作用加以研究。方法:应用携带有人GM—CSF基因的重组腺病毒(R—Ad_5)载体转染BALB/C小鼠肝癌细胞株(H_(22)),体外应用酶联免疫吸附试验(ELISA法)检测GM—CSF表达水平,以GM—CSF基因转染的H_(22)细胞进行致瘤性研究。结果:(1)重组腺病毒载体能成功地介导GM—CSF基因转染H_(22)细胞并能持续有效表达26～31天,瘤苗的辐照处理并不明显影响GM—CSF表达水平。(2)GM—CSF基因转染瘤苗体内致瘤性显著降低。结论:该结果揭示了应用GM—CSF基因转染瘤苗进行肿瘤基因治疗的可行性,为进一步研究肿瘤的GM—CSF基因治疗打下了基础。Purpose: In order to generate cancer vaccine transfected with GM-CSF gene via recombinant adenoviral (R-Ad5) vectors and to examine the antitumor effect of cancer vaccine. Methods: R-Ad5 vectors containing the gene for human GM -CSF are used to infect H22 cells, a hepatocellular carcinoma cell line of BALB/c mice origin. GM-CSF production was mea-sured in vitro by Enzyme-linked immunosorbent assay(ELISA). Tumorigenicity of H22cells transfected with GM-CSF gene via R-Ad5 vectors was studied. Results: (1)R-Ad5 vectors can successfully carry GM-CSF gene into H22cells and efficiently ex-press for 26 to 31 days. Irradiation do not abolish secretion of sufficient GM-CSF levels. (2)Secretion of GM-CSF from the tumor cells abrogated their tumorigenicity. Conclusion:The results indicated the feasibility of cancer gene therapy with expression of GM-CSF gene in tumor cell and provided a basis for further investigation on cancer vaccine.

关 键 词：瘤苗 GM-CSF基因 基因转染 体内致瘤性 腺病毒介导 表达水平 实验研究 肝癌细胞株 肿瘤基因治疗 鼠肝 

分 类 号：R735[医药卫生—肿瘤] R730[医药卫生—临床医学]